BACKGROUND: Cannabis is the illicit drug most frequently reported with impaired driving and motor vehicle accidents. Some "per se" laws make it illegal to drive with any amount of drug in the body, while others establish blood, saliva, or urine concentrations above which it is illegal to drive. The persistence of Δ(9)-tetrahydrocannabinol (THC) in chronic daily cannabis smokers' blood is unknown. METHODS: Thirty male chronic daily cannabis smokers resided on a secure research unit for up to 33 days, with daily blood collection. Samples were processed in an ice bath during sample preparation to minimize cannabinoid adsorption onto precipitant material. We quantified THC by 2-dimensional GC-MS. RESULTS: Of the 30 participants, 27 were THC-positive on admission, with a median (range) concentration of 1.4 μg/L (0.3-6.3). THC decreased gradually; only 1 of 11 participants was negative at 26 days, 2 of 5 remained THC-positive (0.3 μg/L) for 30 days, and 5.0% of participants had THC ≥ 1.0 μg/L for 12 days. Median 11-hydroxy-THC concentrations were 1.1 μg/L on admission, with no results ≥ 1.0 μg/L 24 h later. 11-Nor-9-carboxy-THC (THCCOOH) detection rates were 96.7% on admission, decreasing slowly to 95.7% and 85.7% on days 8 and 22, respectively; 4 of 5 participants remained THCCOOH positive (0.6-2.7 μg/L) after 30 days, and 1 remained positive on discharge at 33 days. CONCLUSIONS: Cannabinoids can be detected in blood of chronic daily cannabis smokers during a month of sustained abstinence. This is consistent with the time course of persisting neurocognitive impairment reported in recent studies.
BACKGROUND: Cannabis is the illicit drug most frequently reported with impaired driving and motor vehicle accidents. Some "per se" laws make it illegal to drive with any amount of drug in the body, while others establish blood, saliva, or urine concentrations above which it is illegal to drive. The persistence of Δ(9)-tetrahydrocannabinol (THC) in chronic daily cannabis smokers' blood is unknown. METHODS: Thirty male chronic daily cannabis smokers resided on a secure research unit for up to 33 days, with daily blood collection. Samples were processed in an ice bath during sample preparation to minimize cannabinoid adsorption onto precipitant material. We quantified THC by 2-dimensional GC-MS. RESULTS: Of the 30 participants, 27 were THC-positive on admission, with a median (range) concentration of 1.4 μg/L (0.3-6.3). THC decreased gradually; only 1 of 11 participants was negative at 26 days, 2 of 5 remained THC-positive (0.3 μg/L) for 30 days, and 5.0% of participants had THC ≥ 1.0 μg/L for 12 days. Median 11-hydroxy-THC concentrations were 1.1 μg/L on admission, with no results ≥ 1.0 μg/L 24 h later. 11-Nor-9-carboxy-THC (THCCOOH) detection rates were 96.7% on admission, decreasing slowly to 95.7% and 85.7% on days 8 and 22, respectively; 4 of 5 participants remained THCCOOH positive (0.6-2.7 μg/L) after 30 days, and 1 remained positive on discharge at 33 days. CONCLUSIONS:Cannabinoids can be detected in blood of chronic daily cannabis smokers during a month of sustained abstinence. This is consistent with the time course of persisting neurocognitive impairment reported in recent studies.
Authors: J Hirvonen; R S Goodwin; C-T Li; G E Terry; S S Zoghbi; C Morse; V W Pike; N D Volkow; M A Huestis; R B Innis Journal: Mol Psychiatry Date: 2011-07-12 Impact factor: 15.992
Authors: Nadia Solowij; Robert S Stephens; Roger A Roffman; Thomas Babor; Ronald Kadden; Michael Miller; Kenneth Christiansen; Bonnie McRee; Janice Vendetti Journal: JAMA Date: 2002-03-06 Impact factor: 56.272
Authors: Olaf H Drummer; Jim Gerostamoulos; Helen Batziris; Mark Chu; John Caplehorn; Michael D Robertson; Philip Swann Journal: Accid Anal Prev Date: 2004-03
Authors: Mark Asbridge; Robert Mann; Michael D Cusimano; Cynthia Trayling; Michael Roerecke; John M Tallon; Alyce Whipp; Jürgen Rehm Journal: Int J Public Health Date: 2013-09-24 Impact factor: 3.380
Authors: Matthew J Smith; Eva C Alden; Amy A Herrold; Andrea Roberts; Dan Stern; Joseph Jones; Allan Barnes; Kailyn P O'Connor; Marilyn A Huestis; Hans C Breiter Journal: J Stud Alcohol Drugs Date: 2018-05 Impact factor: 2.582
Authors: Nora D Volkow; Gene-Jack Wang; Frank Telang; Joanna S Fowler; David Alexoff; Jean Logan; Millard Jayne; Christopher Wong; Dardo Tomasi Journal: Proc Natl Acad Sci U S A Date: 2014-07-14 Impact factor: 11.205
Authors: Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain Journal: Drug Alcohol Depend Date: 2020-04-26 Impact factor: 4.492
Authors: Randi Melissa Schuster; Kevin Potter; Ryan Vandrey; Maya Hareli; Jodi Gilman; David Schoenfeld; A Eden Evins Journal: J Psychopharmacol Date: 2019-09-19 Impact factor: 4.153
Authors: Matthew N Newmeyer; Nathalie A Desrosiers; Dayong Lee; Damodara R Mendu; Allan J Barnes; David A Gorelick; Marilyn A Huestis Journal: Drug Test Anal Date: 2014-03-20 Impact factor: 3.345
Authors: Isabelle Boileau; Esmaeil Mansouri; Belinda Williams; Bernard Le Foll; Pablo Rusjan; Romina Mizrahi; Rachel F Tyndale; Marilyn A Huestis; Doris E Payer; Alan A Wilson; Sylvain Houle; Stephen J Kish; Junchao Tong Journal: Biol Psychiatry Date: 2016-04-25 Impact factor: 13.382